Dwell time 5-10 minutes

Phase 3

Dwell time 5-10 minutes is one of 3 therapeutic programs targeting Bladder (Urothelial, Transitional Cell) Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bladder (urothelial, Transitional Cell) CancerNot yet recruiting

Bladder (urothelial, Transitional Cell) CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Bladder (urothelial, Transitional Cell) Cancer

#DrugCompanyPhaseTrials

TARA-002

PProtara Therapeutics

Phase 3

1 2

Dwell time 5-10 minutes

FFlorian Schroeck

Phase 3

1 3

NDV-01 (sustained-Release Gemcitabine-Docetaxel)

RRelmada Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Not yet recruiting

Bladder (urothelial, Transitional Cell) Cancer

NCT07795255

Clinical

Trials by Indication[1]

Bladder (Urothelial, Transitional Cell) Cancer1 trial

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

Not yet recruiting·FFlorian Schroeck·Phase 3·NCT07795255·1,740 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dwell time 5-10 minutes. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dwell time 5-10 minutes. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Florian Schroeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: FFlorian Schroeck

Dwell time 5-10 minutes

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Bladder (Urothelial, Transitional Cell) Cancer1 trial

References

Drug Info

Quick Facts

Related News